Cspc Innovation Pharmaceutical Stock Cash Flow From Operations
| 300765 Stock | 27.45 0.31 1.14% |
CSPC Innovation Pharmaceutical fundamentals help investors to digest information that contributes to CSPC Innovation's financial success or failures. It also enables traders to predict the movement of CSPC Stock. The fundamental analysis module provides a way to measure CSPC Innovation's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CSPC Innovation stock.
CSPC |
CSPC Innovation Pharmaceutical Company Cash Flow From Operations Analysis
CSPC Innovation's Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current CSPC Innovation Cash Flow From Operations | 927.24 M |
Most of CSPC Innovation's fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CSPC Innovation Pharmaceutical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, CSPC Innovation Pharmaceutical has 927.24 M in Cash Flow From Operations. This is 37.62% higher than that of the Food Products sector and 147.26% higher than that of the Consumer Staples industry. The cash flow from operations for all China stocks is 4.53% higher than that of the company.
CSPC Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CSPC Innovation's direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CSPC Innovation could also be used in its relative valuation, which is a method of valuing CSPC Innovation by comparing valuation metrics of similar companies.CSPC Innovation is currently under evaluation in cash flow from operations category among its peers.
CSPC Fundamentals
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0603 | |||
| Profit Margin | 0.25 % | |||
| Operating Margin | (0.09) % | |||
| Current Valuation | 36.83 B | |||
| Shares Outstanding | 1.4 B | |||
| Shares Owned By Insiders | 78.26 % | |||
| Shares Owned By Institutions | 4.85 % | |||
| Price To Book | 10.00 X | |||
| Price To Sales | 19.14 X | |||
| Revenue | 2.5 B | |||
| Gross Profit | 1.13 B | |||
| EBITDA | 654.85 M | |||
| Net Income | 755.56 M | |||
| Total Debt | 544.96 M | |||
| Book Value Per Share | 2.74 X | |||
| Cash Flow From Operations | 927.24 M | |||
| Earnings Per Share | 0.37 X | |||
| Target Price | 40.96 | |||
| Number Of Employees | 1.89 K | |||
| Beta | -0.14 | |||
| Market Capitalization | 39.12 B | |||
| Total Asset | 5.63 B | |||
| Retained Earnings | 2.55 B | |||
| Working Capital | 3.71 B | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 5.63 B | |||
| Last Dividend Paid | 0.27 |
About CSPC Innovation Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CSPC Innovation Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CSPC Innovation using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CSPC Innovation Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in CSPC Stock
CSPC Innovation financial ratios help investors to determine whether CSPC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CSPC with respect to the benefits of owning CSPC Innovation security.